ScreenerHero

CLDX Celldex Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · celldex.com
30.43USD-1.85%Mkt Cap: 2.39B $P/E: —

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.39B USD
Enterprise Value1.72B USD
Revenue (TTM)158.00K USD
Gross Profit-278.65M USD
Net Income (TTM)-258.76M USD
Revenue/Share0.0020 USD
Last Price30.43 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees198
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.32
PEG—
EV/EBITDA-5.34
EV/Revenue10899.53
P/S15410.18
P/B3.41
EPS (TTM)-4.14
EPS (Forward)-4.24
52W Range
22.1036% of range45.14
52W High45.14 USD
52W Low22.10 USD
Profitability
Gross Margin0.00%
Oper. Margin-366468.20%
EBITDA Margin0.00%
Profit Margin-16748.03%
ROE-49.08%
ROA-44.38%
Growth
Revenue Growth-97.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-210.94M USD
CapEx (TTM)2.71M USD
FCF Margin-84228.16%
FCF Yield-5.57%
Net Debt-712.68M USD
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity0.00
Current Ratio11.82
Quick Ratio11.71
Book Value/Sh9.10 USD
Cash/Share9.14 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 11, 2019
Splits
Last Split1:15
Split DateFeb 11, 2019
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)63.07 USD
Upside (mean)+107.3%
Target Range28.00 USD – 100.00 USD
28.00+107.3% to mean100.00
# Analysts14
Ownership
Shares Out.78.53M
Float73.02M
Insiders0.27%
Institutions110.27%
Short Interest
Short Ratio12.6d
Short % Float13.53%
Short % Out.11.40%
Shares Short8.95M
Short (prev mo.)7.57M
Technical
SMA 5038.14 (-20.2%)
SMA 20032.39 (-6.1%)
Beta0.90
S&P 52W Chg16.45%
Avg Vol (30d)1.64M
Avg Vol (10d)2.18M
Technical Indicators
RSI (14)30.6
MACD-2.0638
MACD Signal-1.8336
MACD Hist.-0.2302
BB Upper41.24 USD
BB Middle34.38 USD
BB Lower27.51 USD
BB Width39.94%
ATR (14)1.745 USD
Vol Ratio (20d)0.83x